SG11202003626RA - Methods of treating a tumor - Google Patents
Methods of treating a tumorInfo
- Publication number
- SG11202003626RA SG11202003626RA SG11202003626RA SG11202003626RA SG11202003626RA SG 11202003626R A SG11202003626R A SG 11202003626RA SG 11202003626R A SG11202003626R A SG 11202003626RA SG 11202003626R A SG11202003626R A SG 11202003626RA SG 11202003626R A SG11202003626R A SG 11202003626RA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- treating
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582174P | 2017-11-06 | 2017-11-06 | |
| US201862629481P | 2018-02-12 | 2018-02-12 | |
| US201862712814P | 2018-07-31 | 2018-07-31 | |
| PCT/US2018/059448 WO2019090330A1 (en) | 2017-11-06 | 2018-11-06 | Methods of treating a tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003626RA true SG11202003626RA (en) | 2020-05-28 |
Family
ID=64427233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003626RA SG11202003626RA (en) | 2017-11-06 | 2018-11-06 | Methods of treating a tumor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210292415A1 (en) |
| EP (1) | EP3706778A1 (en) |
| JP (1) | JP2021502344A (en) |
| KR (1) | KR20200084880A (en) |
| CN (1) | CN111315397A (en) |
| AU (1) | AU2018360790A1 (en) |
| BR (1) | BR112020008316A2 (en) |
| CA (1) | CA3081748A1 (en) |
| IL (1) | IL274314A (en) |
| MX (1) | MX2020004349A (en) |
| SG (1) | SG11202003626RA (en) |
| WO (1) | WO2019090330A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202120128A (en) * | 2019-08-15 | 2021-06-01 | 美商欣爍克斯公司 | Immuno oncology combination therapies with il-2 conjugates |
| BR112023006364A2 (en) * | 2020-10-09 | 2023-05-09 | Synthorx Inc | IMMUNO-ONCOLOGY COMBINATION THERAPY WITH IL-2 AND PEMBROLIZUMAB CONJUGATES |
| KR20230084204A (en) * | 2020-10-09 | 2023-06-12 | 신톡스, 인크. | Immuno-oncology therapy using IL-2 conjugates |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| MXPA05006828A (en) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Antibodies against pd-1 and uses therefor. |
| DE602004024041D1 (en) | 2003-03-05 | 2009-12-24 | Halozyme Inc | SOLUBLE HYALURONIDASE GLYCOPROTEIN (SHASEGP), METHOD OF ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF |
| SI2161336T1 (en) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| BRPI0613361A2 (en) | 2005-07-01 | 2011-01-04 | Medarex Inc | isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| KR20210060670A (en) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| BR122021025338B1 (en) | 2009-11-24 | 2023-03-14 | Medimmune Limited | ISOLATED ANTIBODY OR BINDING FRAGMENT THEREOF AGAINST B7-H1, PHARMACEUTICAL COMPOSITION AND ITS USES |
| KR102472497B1 (en) | 2010-11-12 | 2022-11-29 | 넥타르 테라퓨틱스 | Conjugates of an il-2 moiety and a polymer |
| KR101970025B1 (en) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Antibodies and other molecules that bind b7-h1 and pd-1 |
| HUE051954T2 (en) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| WO2013181634A2 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| DK2992017T3 (en) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1) |
| CN111423511B (en) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-1 |
| CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
| CN107011441B (en) | 2013-09-13 | 2020-12-01 | 百济神州(广州)生物科技有限公司 | anti-PD 1 antibodies and their use as therapeutic and diagnostic agents |
| PT3081576T (en) | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| RS61661B1 (en) | 2014-02-21 | 2021-04-29 | Nektar Therapeutics India Pvt Ltd | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
| CA2971734A1 (en) | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holdings, Inc. | Anti-pd-1 antibodies |
| MA42971A (en) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF |
| US10696745B2 (en) | 2015-06-11 | 2020-06-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Anti-PD-L1 antibodies |
| HUE056201T2 (en) | 2015-07-30 | 2022-02-28 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| US11008391B2 (en) | 2015-08-11 | 2021-05-18 | WuXi Biologics Ireland Limited | Anti-PD-1 antibodies |
| AR105654A1 (en) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH) |
| KR20220131277A (en) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | Anti-pd-1 antibodies and methods of use thereof |
| TWI758267B (en) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| CN108884157A (en) * | 2016-01-11 | 2018-11-23 | 苏黎世大学 | Combination treatment comprising super agonist antibody and checkpoint blocking agent for interleukin-22 |
| CN108697776A (en) | 2016-01-11 | 2018-10-23 | 阿尔莫生物科技股份有限公司 | Interleukin-10 in generating antigentic specificity CD8+T cells and its application method |
| WO2017132825A1 (en) | 2016-02-02 | 2017-08-10 | 华为技术有限公司 | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
-
2018
- 2018-11-06 WO PCT/US2018/059448 patent/WO2019090330A1/en unknown
- 2018-11-06 EP EP18807511.3A patent/EP3706778A1/en not_active Withdrawn
- 2018-11-06 CA CA3081748A patent/CA3081748A1/en active Pending
- 2018-11-06 JP JP2020524530A patent/JP2021502344A/en active Pending
- 2018-11-06 KR KR1020207015988A patent/KR20200084880A/en not_active Application Discontinuation
- 2018-11-06 MX MX2020004349A patent/MX2020004349A/en unknown
- 2018-11-06 BR BR112020008316-0A patent/BR112020008316A2/en not_active IP Right Cessation
- 2018-11-06 AU AU2018360790A patent/AU2018360790A1/en not_active Abandoned
- 2018-11-06 CN CN201880071722.2A patent/CN111315397A/en active Pending
- 2018-11-06 SG SG11202003626RA patent/SG11202003626RA/en unknown
- 2018-11-06 US US16/761,771 patent/US20210292415A1/en not_active Abandoned
-
2020
- 2020-04-28 IL IL274314A patent/IL274314A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL274314A (en) | 2020-06-30 |
| CN111315397A (en) | 2020-06-19 |
| BR112020008316A2 (en) | 2020-10-20 |
| US20210292415A1 (en) | 2021-09-23 |
| CA3081748A1 (en) | 2019-05-09 |
| KR20200084880A (en) | 2020-07-13 |
| MX2020004349A (en) | 2020-10-05 |
| JP2021502344A (en) | 2021-01-28 |
| EP3706778A1 (en) | 2020-09-16 |
| WO2019090330A1 (en) | 2019-05-09 |
| AU2018360790A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269026A (en) | Methods of treating tumor | |
| IL275663A (en) | Methods of treating cancer | |
| HK1258098A1 (en) | Methods of treating cancer | |
| HK1251409A1 (en) | Methods of treating cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| ZA202006746B (en) | Methods of treatment | |
| HK1249051A1 (en) | Method of treating a brain tumor | |
| IL262342A (en) | Methods of treating cancer | |
| ZA201903873B (en) | Methods of treating cochlear synaptopathy | |
| HK1252692A1 (en) | Methods of treating or preventing a proteopathy | |
| IL271934A (en) | Methods of treating tumor metastasis | |
| ZA201908539B (en) | Method of treatment of cancer | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL274314A (en) | Methods of treating a tumor | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL281600A (en) | Methods of treating cancer | |
| IL277981A (en) | Methods of treating cancer | |
| IL269123A (en) | Methods of treating cancer | |
| IL272379A (en) | Methods of treating cancer by inhibiting setd2 | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| ZA201906319B (en) | Methods of treating depression | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| AU2016905189A0 (en) | Methods of treating a tumour | |
| GB201702139D0 (en) | Methods of cancer treatment | |
| GB201711769D0 (en) | Methods of cancer therapy |